Stock search

Ticker or company name

Compare stocks

Market: US

  • INCYIncyte
  • BIIBBiogen
  • MRNAModerna

Add stock

Ticker or company

Summary

INCY
Incyte
$120,27Down −0,58%
Year: Up +15%
44/100Best scoreRatio would watch
Open stock page
BIIB
Biogen
$251,65Down −0,69%
Year: Up +54%
31/100Ratio would not consider buying
Open stock page
MRNA
Moderna
$215,27Down −3,63%
Year: Up +795%
22/100Ratio would not consider buying
Open stock page

Verdict

INCY has the best score (44). INCY grows revenue the fastest. INCY is the cheapest by forward P/E. INCY has the highest net margin. MRNA has 7 of 10 checks in the red zone.

Verdict by our methodology based on current metrics. Not an investment recommendation.

Traffic light — 10 checks

CheckINCY3 ✓ 2 — 4 ✕BIIB1 ✓ 3 — 4 ✕MRNA2 ✓ 0 — 7 ✕
P/E vs its history61,1107,8—
P/E vs industry61,1107,8—
Forward P/E15,516,5n/a—
Revenue growth, YoY+24,9%+2,3%+13,1%
EPS growth, YoY−68,1%−78,9%—
Net margin6,7%3,4%−110,5%
Net debt / EBITDA−4,5n/a——
Free cash flow$745 m$2,07 bn−$1,97 bn
Share count over a year+0,9%+0,5%+10,3%
Cash runwayn/anot neededn/anot needed0,8 yrs

Metrics

Best WorstNo mark — in between

Metric · betterINCYTTMBIIBTTMMRNATTMIndustry medianTTM
P/E TTM ↓Best: 61,1Worst: 107,8n/a42,1
Forward P/E ↓Best: 15,5Worst: 16,5n/a18,7
PEG ↓Best: 4,2Worst: 22,4n/a4,1
P/S TTM ↓4,1Best: 3,6Worst: 35,86,6
EV/EBITDA ↓Best: 32,736,2Worst: 105,928,2
P/FCF ↓Best: 12,822,1Worst: 101,426,0

Price, %

  • INCYn/a
  • BIIBn/a
  • MRNAn/a

Returns

Best WorstNo mark — in between

PeriodINCYBIIBMRNA
1 yearn/an/an/a
3 yearsn/an/an/a
5 yearsn/an/an/a
All timen/an/an/a

“Per year” is the average annual return: 90% growth over 3 years is 23,9% per year, not 30%. “All time” starts at the IPO, so only “per year” compares fairly. Prices adjusted for splits, dividends reinvested.

Analysts and insiders

Best WorstNo mark — in between

INCYBIIBMRNA
Share of “buy”54%Best: 73%Worst: 32%
Beat the forecastWorst: 3 of 4Best: 4 of 4Best: 4 of 4
Average “surprise”Worst: +18,4%+24,0%Best: +43,7%
Insiders over 12 monthssales $65,8 msales $904 829sales $78,9 m

Details are on each stock page.